ZLN005
Modify Date: 2024-01-01 22:40:23
ZLN005 structure
|
Common Name | ZLN005 | ||
|---|---|---|---|---|
| CAS Number | 49671-76-3 | Molecular Weight | 250.338 | |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 415.3±38.0 °C at 760 mmHg | |
| Molecular Formula | C17H18N2 | Melting Point | 257-258℃ | |
| MSDS | Chinese USA | Flash Point | 205.4±13.2 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of ZLN005ZLN005 is a novel transcriptional regulator of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α).IC50 value:Target: PGC-1αin vitro: ZLN005 increases expression of the PGC-1α gene in L6 myotubes. ZLN005 increased PGC-1α mRNA levels in a dose-dependent manner; 20 μmol/L ZLN005 caused a threefold increase over the control after 24 h. At 10 μmol/L, the PGC-1α mRNA levels were increased to almost the same extent at 16 to 48 h [1]. ZLN005 did not increase the expression of the PGC-1α gene in rat primary hepatocytes. AMP-activated protein kinase is involved in the mechanism inducing PGC-1α in L6 myotubes [1]in vivo: An insulin tolerance test revealed that treatment with ZLN005 significantly decreased insulin resistance in db/db mice, as evidenced by the approximately 18% decrease in the AUC. A PTT also was performed in db/db mice, and ZLN005 improved pyruvate tolerance, as evidenced by the 16% decrease in the AUC. In db/db mice, plasma NEFA and triglyceride levels were decreased by 20% and 37%, respectively, and cholesterol was decreased by 10% with ZLN005 treatment. Plasma insulin and β-hydroxybutyrate content, liver/bodyweight index and adipose composition, and muscle and liver triglyceride levels, however, were not ameliorated by treatment with ZLN005 or metformin [1]. |
| Name | 2-(4-tert-butylphenyl)-1H-benzimidazole |
|---|---|
| Synonym | More Synonyms |
| Description | ZLN005 is a novel transcriptional regulator of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α).IC50 value:Target: PGC-1αin vitro: ZLN005 increases expression of the PGC-1α gene in L6 myotubes. ZLN005 increased PGC-1α mRNA levels in a dose-dependent manner; 20 μmol/L ZLN005 caused a threefold increase over the control after 24 h. At 10 μmol/L, the PGC-1α mRNA levels were increased to almost the same extent at 16 to 48 h [1]. ZLN005 did not increase the expression of the PGC-1α gene in rat primary hepatocytes. AMP-activated protein kinase is involved in the mechanism inducing PGC-1α in L6 myotubes [1]in vivo: An insulin tolerance test revealed that treatment with ZLN005 significantly decreased insulin resistance in db/db mice, as evidenced by the approximately 18% decrease in the AUC. A PTT also was performed in db/db mice, and ZLN005 improved pyruvate tolerance, as evidenced by the 16% decrease in the AUC. In db/db mice, plasma NEFA and triglyceride levels were decreased by 20% and 37%, respectively, and cholesterol was decreased by 10% with ZLN005 treatment. Plasma insulin and β-hydroxybutyrate content, liver/bodyweight index and adipose composition, and muscle and liver triglyceride levels, however, were not ameliorated by treatment with ZLN005 or metformin [1]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 415.3±38.0 °C at 760 mmHg |
| Melting Point | 257-258℃ |
| Molecular Formula | C17H18N2 |
| Molecular Weight | 250.338 |
| Flash Point | 205.4±13.2 °C |
| Exact Mass | 250.147003 |
| PSA | 28.68000 |
| LogP | 4.93 |
| Vapour Pressure | 0.0±1.0 mmHg at 25°C |
| Index of Refraction | 1.618 |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302-H319-H413 |
| Precautionary Statements | P305 + P351 + P338 |
| RIDADR | NONH for all modes of transport |
|
~80%
ZLN005 CAS#:49671-76-3 |
| Literature: Du, Li-Hua; Luo, Xi-Ping Synthetic Communications, 2010 , vol. 40, # 19 p. 2880 - 2886 |
|
~99%
ZLN005 CAS#:49671-76-3 |
| Literature: Duefert, M. Alexander; Billingsley, Kelvin L.; Buchwald, Stephen L. Journal of the American Chemical Society, 2013 , vol. 135, # 34 p. 12877 - 12885 |
|
~%
ZLN005 CAS#:49671-76-3 |
| Literature: Shen, Meihua; Driver, Tom G. Organic Letters, 2008 , vol. 10, # 15 p. 3367 - 3370 |
| 2-(4-tert-butylphenyl)-1H-benzimidazole |
| 2-[4-(2-Methyl-2-propanyl)phenyl]-1H-benzimidazole |
| 2-(4-tert-Butylphenyl)-1H-benzimidazole 2-[4-(1,1-Dimethylethyl)phenyl]-1H-benzimidazole |
| 1H-Benzimidazole, 2-[4-(1,1-dimethylethyl)phenyl]- |
| ZLN005 |